The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

Regeneron Pharmaceuticals Inc

Nasdaq: REGN
Last

(U.S.) $370.88

Today's change+4.91 +1.34%
Updated February 10 3:38 PM EST. Delayed by at least 15 minutes.
 

Regeneron Pharmaceuticals Inc

Nasdaq: REGN
Last

(U.S.) $370.88

Today's change+4.91 +1.34%
Updated February 10 3:38 PM EST. Delayed by at least 15 minutes.

Regeneron Pharmaceuticals Inc up (U.S.)$4.91

Regeneron Pharmaceuticals Inc is up today by (U.S.)$4.91 or 1.34% to (U.S.)$370.88. Over the last five days, shares have lost 11.91% and are down 31.68% for the last year to date. This security has outperformed the S&P 500 by 2.99% during the last year.

Key company metrics

  • Open(U.S.) $370.02
  • Previous close(U.S.) $365.97
  • High(U.S.) $378.19
  • Low(U.S.) $363.00
  • Bid / Ask(U.S.) $370.68 / (U.S.) $371.50
  • YTD % change-31.68%
  • Volume968,172
  • Average volume (10-day)1,386,285
  • Average volume (1-month)1,069,328
  • Average volume (3-month)871,624
  • 52-week range(U.S.) $350.26 to (U.S.) $605.93
  • Beta1.18
  • Trailing P/E72.25×
  • P/E 1 year forward27.55×
  • Forward PEG1.38×
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) $5.13
Updated February 10 3:38 PM EST. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
+15.53%

Based on its net profit margin of 15.53%, Regeneron Pharmaceuticals Inc is among the more effective companies in its industry at turning revenues into bottom line profit.
Company Books

S&P TSX0.76%Sector:HealthcareIndustry:Biotechnology
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q3/2015Q2/2015Q1/2015Q4/2014
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedSep 30, 201509/30/2015Jun 30, 201506/30/2015Mar 31, 201503/31/2015Dec 31, 201412/31/2014
Revenue1,137999870802
Total other revenue--------
Total revenue1,137999870802
Gross profit1,028910786743
Total cost of revenue109898459
Total operating expense745670587578
Selling / general / administrative210175159144
Research & development426390343352
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)016123
Other operating expenses, total--------
Operating income392329283225
Interest income (expense), net non-operating-2-3-6-6
Gain (loss) on sale of assets--------
Other--------
Income before tax393328277221
Income after tax21019576110
Income tax, total183133201111
Net income21019576110
Total adjustments to net income--------
Net income before extra. items21019576110
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items21019576110
Inc. avail. to common incl. extra. items21019576110
Diluted net income21019576110
Dilution adjustment------0
Diluted weighted average shares116115115114
Diluted EPS excluding extraordinary itemsvalue per share1.811.690.660.97
Dividends per sharevalue per share0.000.000.000.00
Diluted normalized EPSvalue per share1.811.770.671.07